The Technical AnalystExchange: EURONEXT Industry: Advertising Agencies
Groupe Actiplay SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.24% €0.960
America/New_York / 17 mai 2024 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 15.13 mill |
| EPS: | -1.670 |
| P/E: | -0.570 |
| Earnings Date: | Aug 28, 2024 |
| SharesOutstanding: | 15.76 mill |
| Avg Daily Volume: | 0.110 mill |
| RATING 2024-05-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | n/a | ||||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.570 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -0.570 | industry: PE 17.31 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€-0.120 (-112.49%) €-1.080 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
€ 0.512 - 1.408 ( +/- 46.67%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €0.960 (-2.24% ) |
| Volume | 0.0876 mill |
| Avg. Vol. | 0.110 mill |
| % of Avg. Vol | 79.65 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALACT.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALACT.PA
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.